Analgesic efficacy of peripheral kappa-opioid receptor agonist CR665 compared to oxycodone in a multi-modal, multi-tissue experimental human pain model: selective effect on visceral pain.
about
Will peripherally restricted kappa-opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential?Clinical pharmacology of analgesics assessed with human experimental pain models: bridging basic and clinical research.A cell-based, high-throughput homogeneous time-resolved fluorescence assay for the screening of potential κ-opioid receptor agonists.Differences between opioids: pharmacological, experimental, clinical and economical perspectivesClinical and genetic factors related to cancer-induced bone pain and bone pain relief.Pharmacodynamic effects of oral oxymorphone: abuse liability, analgesic profile and direct physiologic effects in humans.Effects of peripherally restricted κ opioid receptor agonists on pain-related stimulation and depression of behavior in ratsDrug management of visceral pain: concepts from basic research.Effects of peripheral κ opioid receptor activation on inflammatory mechanical hyperalgesia in male and female ratsOpioid Peptides: Potential for Drug Development.Gender, variation in opioid receptor genes and sensitivity to experimental pain.Neoclerodanes as atypical opioid receptor ligandsOptimizing the early phase development of new analgesics by human pain biomarkers.Opioid genetics: the key to personalized pain control?Opioid receptor targeting ligands for pain management: a review and update.Translational pain biomarkers in the early development of new neurotherapeutics for pain management.Treatment of abdominal pain in irritable bowel syndrome.Randomized clinical trial: inhibition of the TRPV1 system in patients with nonerosive gastroesophageal reflux disease and a partial response to PPI treatment is not associated with analgesia to esophageal experimental pain.Randomized clinical trial: efficacy and safety of PPC-5650 on experimental esophageal pain and hyperalgesia in healthy volunteers.Long-Term Reduction of Kappa Opioid Receptor Function by the Biased Ligand, Norbinaltorphimine, Requires c-Jun N-Terminal Kinase Activity and New Protein Synthesis in Peripheral Sensory Neurons.The genetic influences on oxycodone response characteristics in human experimental pain.Pharmacological evaluation of NSAID-induced gastropathy as a "Translatable" model of referred visceral hypersensitivity.Perception and pain thresholds for cutaneous heat and cold, and rectal distension: associations and disassociations.Exploration of the effects of gender and mild esophagitis on esophageal pain thresholds in the normal and sensitized state of asymptomatic young volunteers.Randomised clinical trial: the efficacy of a transient receptor potential vanilloid 1 antagonist AZD1386 in human oesophageal pain.A population pharmacokinetic and pharmacodynamic study of a peripheral κ-opioid receptor agonist CR665 and oxycodone.Nalfurafine is a G-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor.Evaluation of Analgesia, Tolerance, and the Mechanism of Action of Morphine-6-O-Sulfate Across Multiple Pain Modalities in Sprague-Dawley Rats.Oxycodone for prevention of etomidate-induced myoclonus: a randomized double-blind controlled trial.Understanding the Agent, Part I: Opioid Biology and Basic Pharmacology
P2860
Q30250027-0E3F6065-6E7A-41B4-8765-2B222BCCC9C5Q30443497-88AE4AB5-0860-426B-B067-88E235CC7B37Q33869693-158C6C37-55E9-424E-AE22-BB9DC7A10D68Q34272502-2EC4C0D3-FFC6-4ADF-BC5C-90E81074BBA0Q34641014-96F0DDDA-E85E-4C9E-BFB2-2744200896A8Q35252121-46420C9C-5FCD-499E-9280-0EEDAEEDC2FBQ35776817-671D38B5-E18F-4FF9-A13C-4B25CA482162Q35947915-9068F314-0014-43D4-B886-0523DA9B2DDFQ36188108-34BEE676-E949-48AA-A8B2-E1A27C72A909Q36517233-FF0C75B0-46BC-4530-9B3F-C41D3935BA34Q36794010-EECA86DD-DDA4-41BB-ACC5-5E72A5A647BAQ36899819-BCC9EED5-4D87-470A-8DB6-120E341AC95BQ37947690-E3A87B3D-CF8F-4AE0-A9EA-CF2ED291E721Q38025200-30826102-BAC1-4ECB-8E1E-11853D94F3EDQ38028661-8CFCFA67-84F6-4F77-979B-61169DDA0B81Q38184634-158B644E-2271-4326-8753-41AA5EC71383Q38213185-BEEE689C-ADFC-4C56-843F-D0E1B2D94DB9Q38457585-45524A05-FBBD-4FD0-92E4-A4F798718B9CQ39080465-71AD4037-A75D-4023-9A83-C71204C8A0B3Q39412016-EA48CE4B-5CAC-46B6-9E3B-90D5D7305378Q40870241-EA6273AD-5CA8-41F5-BD47-9CBF693EEA45Q42013293-FE5EB27E-FD20-4CB2-9CCB-20B82A772E3CQ43490021-DDCD60C2-CEF6-4E55-B27D-7FCDEF070A9AQ44084798-EE6A365D-8835-4B67-9814-A2A4FA4E7181Q44253395-79C14296-EBFE-4DDE-867F-AF74BA4A4EAEQ44336990-AFE12F2E-874A-4B43-831A-11E5A4BE5161Q44342630-9CD0CAF8-FCD5-4131-8A39-83F90A8EC551Q51010687-C7092CB4-81C1-43AF-8079-47187EB91087Q55333069-D9BB8A8F-3E71-492A-85B4-AB34E0D2B2AFQ57462903-9FB48E2D-194A-40CB-91EB-9AEF34AB5A87
P2860
Analgesic efficacy of peripheral kappa-opioid receptor agonist CR665 compared to oxycodone in a multi-modal, multi-tissue experimental human pain model: selective effect on visceral pain.
description
2009 nî lūn-bûn
@nan
2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Analgesic efficacy of peripher ...... ctive effect on visceral pain.
@ast
Analgesic efficacy of peripher ...... ctive effect on visceral pain.
@en
Analgesic efficacy of peripher ...... ctive effect on visceral pain.
@nl
type
label
Analgesic efficacy of peripher ...... ctive effect on visceral pain.
@ast
Analgesic efficacy of peripher ...... ctive effect on visceral pain.
@en
Analgesic efficacy of peripher ...... ctive effect on visceral pain.
@nl
prefLabel
Analgesic efficacy of peripher ...... ctive effect on visceral pain.
@ast
Analgesic efficacy of peripher ...... ctive effect on visceral pain.
@en
Analgesic efficacy of peripher ...... ctive effect on visceral pain.
@nl
P2093
P50
P1433
P1476
Analgesic efficacy of peripher ...... ctive effect on visceral pain.
@en
P2093
Camilla Staahl
Frédérique Menzaghi
Gilbert Y Wong
Sherron Kell
P304
P356
10.1097/ALN.0B013E3181AF6356
P407
P577
2009-09-01T00:00:00Z